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Approximately 4 million Americans are infected with the
hepatitis C virus (HCV). Most patients with hepatitis C
have no symptoms until cirrhosis is established. Thus,
initial diagnosis and management of hepatitis C rely on
primary care physicians identifying and screening high-risk
individuals. We administered a survey to 1,233 primary
care physicians in a health maintenance organization
(HMO) in April 1997 to assess their knowledge of the risk
factors for HCV infection and approach to the management
of 2 hypothetical HCV antibody–positive patients, 1 with
elevated and the other with normal alanine transaminase
(ALT). Four hundred four (33%) physicians returned the
survey. Ninety percent of respondents correctly identi-
fied the risk factors for HCV infection, but 20% still
considered blood transfusion in 1994 as a significant risk
factor for HCV infection. Sixty-two percent of respondents
would refer HCV antibody–positive patients with abnormal
transaminase levels, but 33% would follow these patients
themselves, even though none of the respondents had
treated any hepatitis C patient on their own. Forty-three
percent of respondents overestimated, while 29% did not
know the efficacy of interferon treatment. Sixty-five percent
of respondents would retest patients for HCV antibody,
regardless of risk factors and transaminase levels. We found
that most primary care physicians correctly identified the
significant risk factors for HCV infection and appropriately
managed the 2 hypothetical patients, but there was consid-
erable confusion about the use of HCV tests and the
effectiveness of treatment. Educational programs for pri-
mary care physicians are needed to implement hepatitis C
screening and to initiate further evaluation and manage-
ment of those who test positive. (HEPATOLOGY 1999;30:794-
800.)
It has been estimated that approximately 4 million Ameri-
cans are infected with the hepatitis C virus (HCV).1 Hepatitis
C accounts for 8,000 to 10,000 deaths annually and is the
leading indication for liver transplantation in the United
States. Significant advances in the diagnosis and treatment of
hepatitis C have been made in the years since the first
diagnostic tests became available in 1990. This rapid growth
of knowledge has taken place without formal standardization
of crucial diagnostic tests or official recommendations for
treatment. The lack of consensus on the best evidence-based
approach to care for patients with hepatitis C led to the
National Institutes of Health (NIH) consensus development
conference in March 1997 and the release of the NIH
consensus statement on hepatitis C.2 The objective of this
conference was to provide health care providers, patients, and
the general public with a responsible assessment of currently
available methods to diagnose and manage hepatitis C.
Many patients with hepatitis C are not aware that they are
at risk for HCV infection. In addition, the vast majority of
patients with hepatitis C have no or nonspecific symptoms
until cirrhosis is established. The occult nature of the disease
in its early stage means that initial diagnosis and management
rely on primary care physicians recognizing and testing
high-risk individuals. It is therefore imperative that primary
care physicians can identify patients at risk for hepatitis C,
institute proper diagnostic testing, and begin initial manage-
ment or referral of these patients. However, the knowledge of
primary care physicians concerning hepatitis C has not been
assessed.
We designed this study to determine: 1) the knowledge
base of primary care physicians on risk factors and manage-
ment of hepatitis C; 2) the factors that influence primary care
physicians’ knowledge and approach to patients with hepati-
tis C; and 3) the effect of the NIH consensus statement on
hepatitis C as an educational intervention in primary care
physicians.
MATERIALS AND METHODS
We developed a survey to assess primary care physicians’ knowl-
edge of the risk factors for HCV infection and their approach to the
management of patients with hepatitis C. The survey contained 9
questions on risk factors and 9 questions on the management of
patients with hepatitis C. A copy of the survey is available from the
authors (T.M.S.). The questions on risk factors listed various
exposures, and the respondents were asked to rate each of the
exposures as ‘‘significant’’ or ‘‘minimal’’ risk factors for HCV infec-
tion. Patient management questions were based on 2 clinical
vignettes of patients who tested positive for HCV antibody by
enzyme-linked immunoabsorbent assay (EIA). The first patient had
normal and the second had elevated alanine transaminase (ALT)
levels (Table 1). The survey also elicited basic demographic informa-
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tion on the respondents, including specialty, years in practice,
number of hepatitis C patients seen in the previous year, and
experience with interferon therapy in hepatitis C patients.
The study comprised 3 phases. First, we used the survey to assess
the baseline knowledge of 1,233 primary care physicians in a large
health maintenance organization (HMO) in Michigan in April 1997.
The list of physicians’ names and addresses was obtained from the
HMO administrative office. The survey was mailed with a cover
letter signed by one of the authors (A.S.-F.L.). The cover letter stated
that the purpose of the survey was to assess the knowledge and
practice of primary care physicians regarding hepatitis C and
assured confidentiality of the results. The baseline knowledge of the
respondents was compared with evidence-supported information in
the NIH consensus statement. In July 1997, we mailed a summary of
the NIH consensus statement to all the physicians who returned the
initial survey. The summary contained 13 pages of text without
illustrations. One month after the mailing of the consensus state-
ment, we sent a new copy of the same survey to all the respondents
and asked them to complete and return the second survey. To
improve the response rate, a reminder was sent 2 weeks after the
mailing of both the initial and the second surveys.
To identify factors that influence the physicians’ responses, the
responses to each question were further analyzed according to the
physicians’ specialty, number of years in practice, and the number of
hepatitis C patients seen in the previous year. To determine if the
responses were influenced by the NIH consensus statement, the
responses between the initial and second surveys were compared.
Statistical comparisons between groups were made using t tests.
RESULTS
Of the 1,233 primary care physicians, 404 (33%) returned
the initial survey. One hundred twenty-six (31%) of those
who responded to the initial survey returned the second
survey.
Respondent Demographics. The majority of the respondents
were family practitioners (48%) or internists (31%) (Table 2).
The remaining respondents were comprised of pediatricians
(17%), general practitioners (3%), and medicine subspecial-
ists (1%). Approximately half (54%) of the respondents had
been in practice for more than 10 years. Most respondents
(84%) had seen less than 5 patients with hepatitis C in the
previous year. At the time of the initial survey, 75% had not
seen the NIH consensus statement, 23% had read excerpts of
it, and only 2% had read the entire statement. The majority
(71%) of the respondents had no experience with interferon
therapy, and none had treated any patient with interferon
without the assistance of a gastroenterologist.
There was no difference between the subgroup of respon-
dents who completed both surveys and the total responder
cohort with regard to specialty, number of years in practice, or
number of hepatitis C patients seen in the previous year
(Table 2). A higher proportion of the subgroup that re-
sponded to both surveys had experience in following patients
treated with interferon. However, fewer members of this
subgroup had seen the NIH consensus statement on hepatitis
C at the time of the initial survey.
Risk Factors for HCV Infection. The respondents were asked
to rate various exposures as ‘‘significant’’ or ‘‘minimal’’ risk
factors for HCV infection (Fig. 1). There was strong agree-
ment between the respondents and the published data that
intravenous drug use (98%), blood transfusion in 1982
(88%), and sexual contact with multiple partners (87%) were
significant risk factors for HCV infection. The vast majority of
the respondents also correctly identified casual household
contact (92%) and sexual contact in a monogamous relation-
ship (93%) as exposures associated with a minimal risk for
HCV infection. Most (80%) respondents considered the risk
of acquiring HCV infection by an infant born to a hepatitis
C–infected mother as significant. A surprisingly high propor-
tion (20%) of the respondents identified blood transfusion in
1994 as a significant risk factor for HCV infection.
When the responses to questions on risk factors were
further analyzed based on the respondents’ specialty, years in
practice, and the number of hepatitis C patients seen during
the previous year, there were significant differences based on
specialty (Fig. 2). A higher proportion of internists correctly
ranked blood transfusion in 1982 as a significant risk factor
for HCV infection, and a lower proportion of internists
ranked blood transfusion in 1994 as a significant risk factor
for HCV infection. Internists were less likely than family
TABLE 1. Summary of the Two Clinical Vignettes
Vignette 1 Vignette 2
55-year-old male 32-year-old female
● Elevated ALT (150 U/L) during
check-up for life insurance
● Subsequent work-up: HCV anti-
body–positive (EIA)
● Otherwise healthy/asymptomatic
● History of intravenous drug use in
1965
● HCV antibody–positive (EIA) at
blood donation
● Subsequent work-up: normal ALT
● Healthy/asymptomatic
● No risk factor










Internal medicine 34 31 30 NS
Family medicine 45 48 52 NS
Other 21 21 18 NS
Number of years in practice
0-5 years 25 24 21 NS
6-10 years 25 22 17 NS
.10 years 50 54 62 NS
Number of hepatitis C
patients seen in the
previous year
None 27 25 NS
1-5 patients 57 56 NS
6-10 patients 11 13 NS
.10 patients 5 6 NS
Experience with alpha
interferon therapy
None 71 43 ,.0001
Followed patients treated
by specialists 27 42 ,.001
Treated patients along
with specialist 2 13 ,.0001
Treat patients alone 0 2 ,.001
Exposure to the NIH con-
sensus statement
Have not seen it 75 83 ,.05
Have read excerpts 23 14 ,.03
Have read the entire
statement 2 3 NS
*Subgroup represents the physicians who responded to both the initial and
second surveys.
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practitioners to identify casual household contact (an expo-
sure with negligible risk) as a significant risk factor for HCV
infection. No significant difference in responses to questions
on risk factors was found based on years in practice or the
number of hepatitis C patients seen in the previous year
(Fig. 3).
In the subgroup of physicians who completed both sur-
veys, the only significant difference between the responses in
the initial and second surveys was a decrease in the propor-
tion of physicians who ranked birth to a hepatitis C–infected
mother as a significant risk factor for HCV infection: 83% vs.
65% (P , .001) (Fig. 4).
Clinical Vignettes. The physicians were asked how they
would manage 2 hypothetical patients who tested positive for
HCV antibody using EIA (Table 1). As expected, the respon-
dents were more likely to refer patient 1 to a gastroenterolo-
gist and to support further intervention, but they were less
certain about the need for and the choice of further HCV
testing in the 2 patients.
Patient 1 had risk factor for HCV infection and abnormal
ALT levels. Nevertheless, when asked what additional HCV
tests should be performed, more than half of the respondents
would recheck for HCV antibody including retesting with
EIA (59%) (Table 3). The majority (82%) of the respondents
would test for HCV RNA. Very few (15%) respondents would
perform HCV genotyping. Most (62%) respondents would
refer patient 1 to a gastroenterologist, but 33% would follow
the patient themselves, even though none of the respondents
had any experience in treating patients with hepatitis C on
their own. An alarming response, albeit from a small minority
(1%) of respondents, was to reassure the patient that he/she is
immune to HCV infection. The vast majority of respondents
would support gastroenterologists’ recommendations to per-
form liver biopsy (89%) and to initiate interferon alfa therapy
FIG. 1. Percent of all respon-
dents (n 5 404) identifying various
exposures as significant risk factors
for HCV infection.
FIG. 2. Percent of all respondents
(n 5 404) identifying various expo-
sures as significant risk factors for
HCV infection based on respondents’
specialty. a vs. b: P 5 .007; a vs. c: P 5
.001; d vs. e: P 5 .02; f vs. g: P 5 .02.
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(84%). However, when asked to estimate the likelihood of a
sustained response after one course of interferon therapy,
43% of the respondents overestimated the response rate,
while 29% did not know the answer.
Patient 2 had normal ALT levels and no identifiable risk
factor for HCV infection, yet the responses to further HCV
testing were remarkably similar to patient 1. Most respon-
dents agreed that confirmatory testing is necessary for this
patient, but they were uncertain which should be the next
test. A similar proportion would retest the patient for HCV
antibody using EIA (68%) or recombinant immunoblot assay
(RIBA) (63%) or for HCV RNA (70%) (Table 3). As expected,
FIG. 3. Percent of all respon-
dents (n 5 404) identifying various
exposures as significant risk factors
for HCV infection based on respon-
dents’ experience with hepatitis C
patients in the past year.
FIG. 4. Percent of respondents
(n 5 126) within the subgroup who
responded to both surveys identify-
ing various exposures as significant
risk factors for HCV infection in the
initial and second surveys. *P , .05.
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only a minority (18%) of the respondents would refer patient
2 to a gastroenterologist; most (75%) would follow the
patient in their clinics. Contrary to patient 1, only one third
of the respondents would support further intervention such
as liver biopsy (39%) or interferon treatment (36%), even if
recommended by a gastroenterologist.
To identify the factors that may influence the management
of patients with hepatitis C, physician responses were further
analyzed according to their specialty, years in practice, and
number of hepatitis C patients seen in the previous year
(Table 4). Internists were more likely to refer patient 1 to a
gastroenterologist compared with other physicians. Internists
and physicians who had seen more patients with hepatitis C
were less likely to answer that they ‘‘did not know’’ when
asked to estimate the likelihood of response to interferon
therapy. The management of patient 2 was considerably more
uniform irrespective of the physicians’ specialty (Table 4),
years in practice (Table 5), or number of hepatitis C patients
seen in the previous year.
The responses on management of the 2 patients were
similar in the initial and second surveys (Table 6).
DISCUSSION
In this study, we attempted to define the knowledge base of
primary care physicians on risk factors and management of
hepatitis C. As the ‘‘gatekeepers’’ to the health care system in
the United States, primary care physicians must be able to
identify patients at risk for hepatitis C and institute proper
diagnostic testing and referral. The respondents in this study
were able to identify most hepatitis C risk factors, but
demonstrated considerable confusion over confirmatory test-
ing and efficacy of treatment.
The HMO studied in this project was chosen because of the
diversity of patients enrolled, the variety of practice settings
represented, and its size. The demographics of the patients
covered by this HMO are similar to the age and gender
breakdown of the Michigan population. The study popula-
tion represented over 1,200 physicians, with 404 physicians
responding. This response rate of 33% is comparable with the
TABLE 3. Management of Patients With Hepatitis C
Percent of Respondents
Vignette 1 Vignette 2
At this point your next step would be to
Reassure patient that s/he is immune to hepa-
titis C 1 3
Follow patient in clinic, no referral 8 37
Follow in clinic, refer if symptoms develop 25 38
Refer to a gastroenterologist 62 18
Don’t know 4 4
Assume that you decided to do further testing; which tests would you per-
form next (check all that apply)
Recheck HCV antibody by EIA 59 68
Quantitative/qualitative test for HCV RNA 82 70
Recheck for HCV antibody with RIBA 64 63
HCV genotyping 15 14
Would you support a liver biopsy if recommended by a gastroenterologist
Yes 89 39
No 11 61




If patient is treated, what is the likelihood of sustained response after
completion of a course of interferon









Vignette 1 Vignette 2
Would you refer patient to a gastroenterologist?
Internal medicine 70 15
Family practice 59 19
Other 51 18
Would you support a liver biopsy if recommended
by a gastroenterologist?
Internal medicine 86 34
Family practice 88 41
Other 79 29
Would you support interferon therapy if recom-
mended by a gastroenterologist?
Internal medicine 77 29
Family practice 84 33
Other 74 32
What is the likelihood of sustained response after
completing a course of interferon. (% answer-
ing—Don’t know)
Internal medicine 16 Not asked
Family practice 28
Other 45




Vignette 1 Vignette 2
Would you refer patient to a gastroenterologist?




Would you support a liver biopsy if recommended
by a gastroenterologist?




Would you support interferon therapy if recom-
mended by a gastroenterologist?




What is the likelihood of a sustained response
after completion of a course of interferon?
(% answering don’t know)
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response rate of 30% in a study on primary care physicians’
knowledge and practice patterns concerning Helicobacter
pylori infection.3 A higher response rate of 57% was obtained
in a survey on management of patients with hepatitis C
among gastroenterologists.4 This may be related to the
increased awareness of hepatitis C among gastroenterologists
and the fact that the survey was conducted by the NIH and
the American Gastroenterology Association on the AGA
members. Despite the low response rate, we feel that our
respondents were representative of the physicians in the
HMO studied. The demographics of the 404 responding
physicians were similar to that of the entire physician
workforce of the HMO in terms of specialty, practice location,
and years in practice (Table 2). The demographics of the
subgroup of respondents who returned both surveys were
also comparable with the total responding cohort (Table 2).
The vast majority (90%) of our respondents correctly
identified intravenous drug use, blood transfusion before
1990, and multiple sex partners as significant risk factors,
and casual household contact and monogamous sexual
contact as exposures with low risk for HCV infection.
Although the risk of perinatal transmission of hepatitis C is
only 6%,5 over 80% of the respondents considered this to be a
significant risk factor. While the Centers for Diseases Control
(CDC) recommends screening offspring of HCV-infected
women,6 it is important that primary care physicians cor-
rectly counsel these women that the risk of transmission is
below 10% and that pregnancy, vaginal delivery, and breast-
feeding should not be discouraged. Of greater concern is that
20% of the cohort still considered a blood transfusion in
1994, 4 years after implementation of blood donor screening
for HCV antibody and 2 years after using more reliable
second-generation EIA testing, as a significant risk factor for
HCV infection. Currently, the risk of transmitting HCV
infection through blood transfusion in the United States is
estimated to be 1/100,000.7 Overestimation of the risk of
blood transfusion may result in unnecessary refusal of
potentially life-saving blood products. Comparisons between
the two surveys found that the only difference in responses
was a significant decrease in respondents ranking birth to an
HCV-infected mother as a significant risk factor for HCV
infection in the second survey. The exact reason(s) for the
change in response is not clear. The respondents may have
acquired new information between the two surveys, but the
responses to other questions in the survey were unchanged. It
is possible that the high percent of pediatricians and family
practitioners among the respondents may have led to a search
for information that has direct relevance to their practice,
such as the risk of perinatal transmission of HCV infection.
Finally, the perception of what constitutes a significant risk
factor may have changed with time.
While the majority of respondents correctly identified the
risk factors for HCV infection, our study did not address their
accuracy in identifying these risk factors. Many studies have
found that patients are often evasive about their history of
drug or alcohol use. A recent study reported that 40% of
blood donors who initially denied history of intravenous
drug use subsequently admitted to having used intravenous
drugs when interviewed after they tested positive for HCV
antibody.8 Carefully worded direct questioning is often neces-
sary to elicit history of remote use of intravenous drugs.
Exhaustive history-taking to identify potential risk factors for
HCV infection depends on the level of suspicion and the
physicians’ perception of the importance of identifying these
factors. Even after risk factors are identified, documentation
of the information may be influenced by concerns about the
confidentiality of the medical records and the potential
impact of the information on future health care/employment.
Our survey did not include questions on how often primary
care physicians include risk factors for HCV infection in their
histories or whether screening is performed if risk factors are
present, a practice that is recommended by the Centers for
Diseases Control and the NIH consensus statement.2,7
The NIH consensus statement recommended liver biopsy
and consideration for treatment in patient 1 and further
testing to confirm the diagnosis of chronic HCV infection in
patient 2.2 Liver biopsy and interferon treatment is not
recommended for patient 2 if ALT levels are persistently
normal.2,9 As expected, most of our respondents recognized
the difference in need for referral to a gastroenterologist and
for intervention between the 2 patients. However, 38% of the
respondents would not refer patient 1, even though none of
them had any experience in treating hepatitis C patients on
their own. The reluctance in referring patient 1 is surprising,
because most (72%) respondents had no idea or overesti-
mated the effectiveness of interferon therapy. We did not
define sustained response or the dose and duration of a
course of interferon therapy in the survey. At the time this
survey was conducted, interferon monotherapy administered
for 1 year was the standard, with rates of sustained biochemi-
cal and virological response being 15% to 25% and 10% to
20%, respectively.10-12
The biggest concern with regards to the responses in the
two vignettes is the confusion about the use of hepatitis C
tests. While the choice of further tests may depend on the
primary care physicians’ plans to refer or not to refer their
patients to specialists, our question specifically asked, ‘‘As-
sume you decide to do further testing, which tests would you
perform?’’ Inappropriate use of HCV tests may lead to
misdiagnosis, unnecessary testing, and delays in treatment.
Patient 1 had risk factors for HCV infection and an abnormal
ALT level. Further testing to confirm the diagnosis of HCV
infection is, strictly speaking, unnecessary.13,14 However,
HCV-RNA testing is recommended if treatment is contem-
plated. Patient 2 had a normal ALT level and no identifiable
risk factor. Further testing to confirm the diagnosis of chronic
TABLE 6. Management of Hepatitis C Patients: Comparison of Responses
in the Initial and Second Surveys (n 5 126)
Percent of Respondents Replying Yes
Vignette 1 Vignette 2
Initial Second Initial Second
Would you refer patient to a gastro-
enterologist? 61 68 19 20
Would you support a liver biopsy if
recommended by a gastroenter-
ologist? 89 92 42 45
Would you support interferon
therapy if recommended by a
gastroenterologist? 85 83 31 36
What is the likelihood of sustained
response after completing a
course of interferon? (% answer-
ing—Don’t know) 26 19 Not asked
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HCV infection is mandatory.13,14 The NIH consensus state-
ment recommends retesting for HCV antibody using RIBA.2
This test is more specific than EIA. Patients with a negative
RIBA result can be reassured, and no further evaluation is
necessary. Those who have a positive or indeterminate RIBA
result should be further tested for HCV RNA to determine if
they are still infected. There is no value in repeating the EIA
test. Although studies published in the last year suggest that
knowledge of the patients’ HCV genotype may influence the
choice and duration of treatment,15,16 the NIH consensus
statement did not recommend HCV genotyping in clinical
practice based on data available up to March 1997.
In summary, our study found that the majority of primary
care physicians correctly identified the significant risk factors
for HCV infection. However, up to 20% of the respondents
still regarded blood transfusion after 1992 and a small but
disturbingly high (8%) proportion considered casual house-
hold contact as a significant risk factor for HCV infection.
Our study found that most primary care physicians recognize
the need to refer HCV antibody–positive patients who have
abnormal ALT levels and would support liver biopsy and
interferon treatment if recommended by a gastroenterologist.
Nevertheless, 38% of primary care physicians would not refer
such patients. We also found considerable confusion about
the use of HCV tests and the effectiveness of treatment for
hepatitis C. Our data indicate that educational initiatives for
primary care physicians are needed to implement the NIH
and Centers for Diseases Control’s recommendations on
hepatitis C screening and to initiate further evaluation and
management of those who test positive. We found that
primary care physicians’ knowledge of hepatitis C risk factors
and management of patients who test positive for HCV
antibody are remarkably similar regardless of their specialty,
years in practice, and number of hepatitis C patients seen in
the previous year.
Because of the small size of our study cohort and the fact
that our study was confined to one HMO, we are not certain if
our findings can be generalized to primary care physicians
across the country. The lack of improvement in responses to
‘‘error-prone’’ questions in the second survey suggests that
mailing of an information package is not a very effective
educational tool. This may be related to the unappealing
nature of 13 pages of black-and-white text, because the
proportion of respondents who have read the entire NIH
consensus statement increased from 2% to 22% only between
the initial and second surveys. In addition to our intervention
effort, many original and review articles on hepatitis C were
published in the medical literature during our study period.
Our results suggest that more effective educational programs
with or without incentives such as continuing medical
education credits are needed to improve primary care physi-
cians’ knowledge and understanding of hepatitis C. Other
studies have demonstrated that knowledge acquisition and
behavioral changes are greater in educational programs that
actively involve the learner, such as case-based discussions or
interactive lectures.17,18 Our study was conducted in mid-
1997, before major educational campaigns on hepatitis C. It
is possible that primary care physicians’ awareness and
knowledge of hepatitis C have improved since our study as a
result of educational efforts by professional organizations and
propaganda in the media during the past year.
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